Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort - Top-Institutions - MDSpire

Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort

  • By

  • Cheng Tian

  • Lizheng Xiang

  • Shengchun Liu

  • Haochen Yu

  • May 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    First Affiliated Hospital of Chongqing Medical University
    First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing

    Key Differentiators

    • Oncology

  • #2

    Cancer and Leukemia Group B
    Cancer and Leukemia Group B

    Chicago, Illinois

    Key Differentiators

    • Oncology

  • #3

    Yale University School of Medicine
    Yale University School of Medicine

    New Haven, Connecticut

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #5

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort

  • by Cheng Tian, Lizheng Xiang, Shengchun Liu, Haochen Yu

  • May 11, 2026

Related Content

Multi-parametric MRI habitat radiomics with interpretable machine learning for early prediction of axillary lymph node metastasis in triple-negative breast cancer

Development and internal validation of a risk prediction model for ipsilateral upper-limb lymphedema following breast cancer surgery

Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells